Euclidean Capital LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Euclidean Capital LLC reported 11 stock positions worth $369.4 million. Its top holding was Vanguard Ftse All-World Ex-U (VEU) at 59.5% of the portfolio, followed by Vanguard Mrngstr Val ETF-Aui (VTV, 26.9%) and iShares MSCI India ETF (INDA, 5.4%). Compared with Q3 2025, it opened 1 new position and added to 1. The biggest buy was a new position in Vanguard Mrngstr Val ETF-Aui (VTV).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001825034
- Portfolio Value
- $369.4M (Q4 2025)
- SEC Filing
- 0001012975-26-000154 ↗ filed Feb 17, 2026
Holdings Value
Holdings 11 stocks · $369.4M
| VEU Vanguard Ftse All-World Ex-U | 59.53% | 2,990,084 | $220.0M | Add +16.0% |
| VTV Vanguard Mrngstr Val ETF-Aui | 26.88% | 520,000 | $99.3M | New |
| INDA iShares MSCI India ETF | 5.41% | 369,600 | $20.0M | No change |
| FHTX Foghorn Therapeutics Inc. | 2.30% | 1,573,761 | $8.5M | No change |
| ORIC Oric Pharmaceuticals Inc. | 2.19% | 989,410 | $8.1M | No change |
| PMVP PMV Pharmaceuticals Inc. | 0.89% | 2,627,643 | $3.3M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 0.76% | 4,104 | $2.8M | No change |
| RAPT Rapt Therapeutics Inc. | 0.75% | 82,234 | $2.8M | No change |
| ALEC Alector Inc. | 0.55% | 1,307,858 | $2.0M | No change |
| SRZN Surrozen Inc. | 0.54% | 87,696 | $2.0M | No change |
| TNYA Tenaya Therapeutics Inc. | 0.20% | 1,015,705 | $723K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $3K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 170,833 | $3K | No change |
Total filed on the 13F, all lines: $369.5M.
Portfolio Sells Q3 2025 → Q4 2025
| None this quarter. | |||
Portfolio Buys Q3 2025 → Q4 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $439.8M | VEU, VTV, INDA, ORIC, TMS |
| Q1 2026 | 9 | $392.3M | VEU, VTV, INDA, ORIC, FHTX |
| Q4 2025 | 11 | $369.4M | VEU, VTV, INDA, FHTX, ORIC |
| Q3 2025 | 10 | $238.0M | VEU, INDA, ORIC, FHTX, ALEC |
| Q2 2025 | 10 | $305.7M | VEU, INDA, ORIC, FHTX, PMVP |
| Q1 2025 | 10 | $266.1M | INDA, VEU, FHTX, ORIC, PMVP |
| Q4 2024 | 10 | $736.7M | SPY, INDA, VEU, ORIC, FHTX |
| Q3 2024 | 11 | $906.8M | SPY, INDA, VEU, FHTX, ORIC |
| Q2 2024 | 10 | $795.8M | SPY, INDA, FHTX, ORIC, ALEC |
| Q1 2024 | 12 | $780.0M | SPY, INDA, GLD, ORIC, FHTX |